EDISON EQUITY RESEARCH - THRESHOLD PHARMACEUTICALS
September 17 2015 - 8:41AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: THRESHOLD PHARMACEUTICALS -
TARLOXOTINIB ADVANCES INTO TWO PHASE II TRIALS
Tarloxitinib (TH-4000), Threshold’s earlier-stage hypoxia asset,
has now started two Phase II studies, as planned. With active
development now ongoing we include an indicative valuation for this
asset in our rNPV, which has increased to $1,023m ($14.3/share).
Tarloxotinib broadens and diversifies Threshold’s pipeline beyond
evofosfamide, where we continue to expect the number of events
needed for analysis of the Phase III STS and pancreatic trials
should be reached in H215, with data shortly after.
Threshold Pharmaceuticals is a US oncology company focused on
tumour hypoxia, a low-oxygen condition found in most solid tumours
and some blood cancers. Evofosfamide is in Phase III for STS and
pancreatic cancer and earlier trials in multiple other cancers, and
is partnered with Merck KGaA.
To view our full report, please click here
Click here to view all of Edison
Investment Research’s published reports
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2023 to Apr 2024